Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PharmaCell Wins ImmunoCellular Contract for Phase III Program | Contract Pharma

What are you searching for?

Sign in
Breaking News

PharmaCell Wins ImmunoCellular Contract for Phase III Program

Will perform tech transfer and support clinical trial for ICT-107

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PharmaCell B.V. has entered an agreement with ImmunoCellular Therapeutics Ltd. to support its Phase III trial in Europe for ICT-107, a dendritic cell-based vaccine developed for glioblastoma multiforme, one of the most common and deadliest forms of brain cancer.
 
PharmaCell will perform a technology transfer from its U.S.-based contract manufacturing partner to its newly acquired Geleen facility in The Netherlands, and support the subsequent clinical trial for ICT-107.
 
Andrew Gengos, chief executive officer of ImmunoCellular Therapeutics said, “We are pleased to engage with PharmaCell who have a proven ability to support companies in establishing a robust manufacturing capability in Europe in line with the strict standards of the regulatory authorities for Phase III and early stage commercial manufacturing for ATMPs (Advanced Therapy Medicinal Products).”
 
Alexander Vos, chief executive officer of PharmaCell BV, said, “We are excited that ImmunoCellular Therapeutics, a global leader in cancer immunotherapy, have decided to work with us. Their decision confirms that our new Geleen facility is indeed viewed by industry experts as meeting the requirements and client expectations for late clinical stage and commercial manufacturing for ATMPs. We look forward to support ImmunoCellular in their effort to develop ICT-107 for the benefit of European patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics